Marco Zecca
Distinguished in Chromosome 7p Deletion

Marco Zecca

Pavia, IT 
Distinguished in Chromosome 7p Deletion
Pavia, IT 
OverviewLocationsClinical Research

Overview

Marco Zecca practices in Pavia, Italy. Mr. Zecca is rated as a Distinguished expert by MediFind in the treatment of Chromosome 7p Deletion. His top areas of expertise are Juvenile Myelomonocytic Leukemia (JMML), Anemia, Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Splenectomy.

His clinical research consists of co-authoring 263 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Chromosome 7p Deletion.

Gender
Male

Locations

Pavia, Italy
Other Locations
Padova, Italy
Modena, Italy
San Matteo, Italy
Rome, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Prospective Observational Study for Evaluating Incidence, Severity and Outcomes of Chronic Graft-versus-Host Disease According to 2015 NIH Consensus Criteria
A Prospective Observational Study for Evaluating Incidence, Severity and Outcomes of Chronic Graft-versus-Host Disease According to 2015 NIH Consensus Criteria
Enrollment Status: Completed
Publish Date: November 25, 2022
A Clinical Study to Investigate Interferon Gamma (IFNɣ) Signature in Patients Post HSCT and in Patients With Impaired HSC Proliferation Pre-transplant
A Clinical Study to Investigate Interferon Gamma (IFNɣ) Signature in Patients Post HSCT and in Patients With Impaired HSC Proliferation Pre-transplant
Enrollment Status: Terminated
Publish Date: October 21, 2022
Intervention Type: Procedure
A Multi-centre, Multinational, Prospective Observational Registry to Collect Safety and Outcome Data in Patients Diagnosed With Severe Hepatic Veno-occlusive Disease (VOD) Following Hematopoietic Stem Cell Transplantation (HSCT) and Treated With Defitelio®
A Multi-centre, Multinational, Prospective Observational Registry to Collect Safety and Outcome Data in Patients Diagnosed With Severe Hepatic Veno-occlusive Disease (VOD) Following Hematopoietic Stem Cell Transplantation (HSCT) and Treated With Defitelio®
Enrollment Status: Completed
Publish Date: October 16, 2019
View 2 Less Clinical Trials

263 Total Publications

Autoantibodies neutralizing type I IFNs in 40% of patients with WNV encephalitis in seven new cohorts.
Autoantibodies neutralizing type I IFNs in 40% of patients with WNV encephalitis in seven new cohorts.
Journal: medRxiv : the preprint server for health sciences
Published: September 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Zecca's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 26 Advanced Conditions
View All 53 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile